Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Dow
McKesson
AstraZeneca
Merck

Last Updated: August 17, 2022

CLINICAL TRIALS PROFILE FOR CEVIMELINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Cevimeline

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00017511 ↗ Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed Daiichi Sankyo Inc. Phase 3 2001-06-01 RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of cevimeline in treating patients who have dryness of the mouth caused by radiation therapy for head and neck cancer.
NCT00017511 ↗ Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed Daiichi Sankyo, Inc. Phase 3 2001-06-01 RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of cevimeline in treating patients who have dryness of the mouth caused by radiation therapy for head and neck cancer.
NCT00466388 ↗ Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed Duke University Phase 4 2007-05-01 The purpose of this study is to determine the effectiveness of cevimeline (versus placebo) on the oral health of patients who have dry mouth which was caused by radiation therapy that was given for treatment of head and/or neck cancer.
NCT00466388 ↗ Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed American Academy of Otolaryngology-Head and Neck Surgery Foundation Phase 4 2007-05-01 The purpose of this study is to determine the effectiveness of cevimeline (versus placebo) on the oral health of patients who have dry mouth which was caused by radiation therapy that was given for treatment of head and/or neck cancer.
NCT01690052 ↗ Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva Completed University of Kentucky N/A 2009-01-01 The main objectives were: 1) To determine the efficacy of both cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia, and 2) To compare the side-effects between the treatment for xerostomia with cevimeline and with pilocarpine.
NCT01903109 ↗ Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions Completed Roxane Laboratories Early Phase 1 2009-02-01 The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cevimeline

Condition Name

Condition Name for Cevimeline
Intervention Trials
Dry Mouth 3
Head and Neck Cancer 1
Oral Complications 1
Overactive Bladder Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cevimeline
Intervention Trials
Xerostomia 4
Syndrome 1
Sjogren's Syndrome 1
Radiation Injuries 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cevimeline

Trials by Country

Trials by Country for Cevimeline
Location Trials
United States 43
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cevimeline
Location Trials
Kentucky 3
Illinois 2
Colorado 2
Nevada 2
Virginia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cevimeline

Clinical Trial Phase

Clinical Trial Phase for Cevimeline
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
N/A 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cevimeline
Clinical Trial Phase Trials
Completed 5
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cevimeline

Sponsor Name

Sponsor Name for Cevimeline
Sponsor Trials
Roxane Laboratories 2
University of Kentucky 1
China Medical University Hospital 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cevimeline
Sponsor Trials
Industry 4
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Baxter
AstraZeneca
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.